High Cholesterol

Clinical Trial Finder

Many patients with high cholesterol are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Efficacy/Safety of DP-R207 Tablet Versus CRESTOR Tablet in Patients With Primary Hypercholesterolemia

Condition:   Primary Hypercholesterolemia
Interventions:   Drug: Rosuvastatin 5mg;   Drug: DP-R207 5/10mg;   Drug: Rosuvastatin 10mg;   Drug: DP-R207 10/10mg;   Drug: Rosuvastatin 20mg;   Drug: DP-R207 20/10mg;   Drug: Placebo (for Rosuvastatin 5mg and DP-R207 5/10mg);   Drug: Placebo (for Rosuvastatin 10mg and DP-R207 10/10mg);   Drug: Placebo (for Rosuvastatin 20mg and DP-R207 20/10mg)
Sponsor:   DreamPharma
Completed - verified May 2015

Clinical Trial to Evaluate the Efficacy and Safety of CKD-391

Condition:   Hyperlipidemia
Interventions:   Drug: Atorvastatin10mg, Ezetimibe10mg;   Drug: Atorvastatin10mg, Ezetimibe placebo;   Drug: Atorvastatin20mg, Ezetimibe10mg;   Drug: Atorvastatin20mg, Ezetimibe placebo;   Drug: Atorvastatin40mg, Ezetimibe10mg;   Drug: Atorvastatin40mg, Ezetimibe placebo
Sponsor:   Chong Kun Dang Pharmaceutical
Recruiting - verified May 2015

Relationship Between Insulin Resistance and Statin Induced Type 2 Diabetes, and Integrative Personal Omics Profiling

Condition:   Hyperlipidemia
Intervention:   Drug: Atorvastatin
Sponsor:   Stanford University
Recruiting - verified May 2015

Trial Assessing Efficacy, Safety and Tolerability of PCSK9 Inhibition in Paediatric Subjects With Genetic LDL Disorders

Condition:   Heterozygous Familial Hypercholesterolemia
Interventions:   Drug: Evolocumab;   Drug: Placebo
Sponsor:   Amgen
Not yet recruiting - verified May 2015

A Phase 1 Study of an Investigational Drug, ALN-PCSSC, in Subjects With Elevated Low Density Lipoprotein Cholesterol (LDL-C)

Condition:   Hypercholesterolemia
Interventions:   Drug: ALN-PCSSC;   Drug: Sterile Normal Saline (0.9% NaCl)
Sponsors:   Alnylam Pharmaceuticals;   The Medicines Company
Active, not recruiting - verified May 2015

Evaluation of Alirocumab in Addition to Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia in South Korea and Taiwan

Condition:   Hypercholesterolemia
Interventions:   Drug: alirocumab SAR236553/REGN727;   Drug: placebo
Sponsor:   Sanofi
Recruiting - verified May 2015

Extension (OLE) Study to Assess Safety and Efficacy of Evolocumab

Condition:   Hypercholesterolemia
Intervention:   Biological: Evolocumab
Sponsor:   Amgen
Enrolling by invitation - verified May 2015

Cardiovascular and Renal Risk in Spain

Condition:   Cardiovascular Disease
Intervention:   Other: No treatment
Sponsor:   La Sociedad Española de Médicos de Atención Primaria
Recruiting - verified October 2014

A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol

Condition:   Hyperlipidemia
Interventions:   Drug: Evacetrapib;   Drug: Atorvastatin;   Drug: Ezetimibe;   Drug: Placebo
Sponsor:   Eli Lilly and Company
Recruiting - verified May 2015

CEntralized Pan-Russian Survey of tHE Undertreatment of hypercholeSterolemia II (CEPHEUS II)

Condition:   Dyslipidaemia
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified May 2015

Extended Pouch Roux-en-Y Gastric Bypass Study

Condition:   Morbid Obesity
Interventions:   Procedure: Extended Pouch RYGB;   Procedure: Standard RYGB
Sponsor:   Rijnstate Hospital
Recruiting - verified August 2014

Study to Evaluate Efficacy and Safety of PreLipid® on Subjects With Higher Than Normal Blood Lipid Levels

Condition:   Hyperlipidemia
Interventions:   Dietary Supplement: Study Dietary Supplement (Prelipid 500 mg capsules);   Dietary Supplement: Placebo
Sponsors:   PreEmptive Meds, Pvt. Ltd;   Abbott
Completed - verified May 2015

Healing and Empowering Alaskan Lives Towards Healthy-Hearts Study

Condition:   Tobacco Dependence
Interventions:   Behavioral: Counselor intervention for tobacco/physical activity;   Drug: Nicotine replacement therapy;   Behavioral: Intervention for managing hypertension/hypercholesterolemia
Sponsors:   Stanford University;   University of California, San Francisco;   Alaska Native Tribal Health Consortium;   University of Alaska Anchorage;   Norton Sound Health Corporation
Not yet recruiting - verified May 2015

Efficacy and Safety Evaluation of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia or High Cardiovascular Risk Patients With Hypercholesterolemia on Lipid Modifying Therapy

Condition:   Hypercholesterolemia
Interventions:   Drug: Placebo (for alirocumab);   Drug: Alirocumab;   Drug: Statin therapy
Sponsors:   Sanofi;   Regeneron Pharmaceuticals
Active, not recruiting - verified May 2015

Phase III Study To Evaluate Alirocumab in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE II)

Condition:   Hypercholesterolemia
Interventions:   Drug: Alirocumab;   Drug: Placebo (for alirocumab)
Sponsors:   Sanofi;   Regeneron Pharmaceuticals
Active, not recruiting - verified May 2015

A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia

Condition:   Heterozygous Familial Hypercholesterolemia
Interventions:   Drug: Bococizumab (PF-04950615;RN316);   Other: Placebo
Sponsor:   Pfizer
Active, not recruiting - verified May 2015

Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events

Condition:   Hyperlipidemia
Interventions:   Drug: Bococizumab (PF-04950615; RN316);   Other: Placebo
Sponsor:   Pfizer
Recruiting - verified May 2015

Randomized Clinical Trial Of Bococizumab (PF-04950615; RN316) In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events

Condition:   Hyperlipidemia
Interventions:   Drug: Bococizumab (PF-04950615;RN316);   Other: Placebo
Sponsor:   Pfizer
Recruiting - verified May 2015

Open Label Study of Long Term Safety Evaluation of Alirocumab

Condition:   Hypercholesterolemia
Intervention:   Drug: Alirocumab SAR236553 (REGN727)
Sponsors:   Sanofi;   Regeneron Pharmaceuticals
Recruiting - verified May 2015

A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-050)

Condition:   Heterozygous Familial Hypercholesterolemia (HeFH)
Interventions:   Drug: Anacetrapib;   Drug: Placebo for anacetrapib
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified May 2015

Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk

Condition:   Dyslipidemia
Interventions:   Biological: Evolocumab (AMG 145);   Other: Placebo;   Drug: Effective statin therapy
Sponsor:   Amgen
Recruiting - verified May 2015

Effect of Long Biliopancreatic Limb RYGB on Weight Loss and Comorbidities

Condition:   Morbid Obesity
Intervention:   Procedure: Roux-en-Y Gastric Bypass
Sponsor:   Rijnstate Hospital
Active, not recruiting - verified March 2014

Atorvastatin, Aspirin, Oxidative Stress, Coagulation and Platelet Activation Indexes

Conditions:   Type 2 Diabetes Mellitus;   Hypercholesterolemia
Interventions:   Drug: Atorvastatin;   Drug: Placebo
Sponsor:   University of Roma La Sapienza
Active, not recruiting - verified May 2015

Statins in Children With Type 1 Diabetes and Hypercholesterolemia

Conditions:   Diabetes Mellitus, Insulin-Dependent;   Hypercholesterolemia
Interventions:   Drug: Atorvastatin;   Drug: Atorvastatin Placebo
Sponsors:   Nemours Children's Clinic;   Pfizer;   Medtronic;   Quest Diagnostics
Completed - verified May 2015

Interval Training in Young Healthy Individuals

Conditions:   Healthy Subjects;   Exercise Test
Interventions:   Behavioral: High frequency training;   Behavioral: normal frequence training
Sponsor:   Norwegian University of Science and Technology
Completed - verified May 2015

Trial of a Cardiac Rehabilitation Program Delivered Remotely Through the Internet

Condition:   Cardiovascular Disease
Intervention:   Behavioral: vCRP
Sponsors:   Simon Fraser University;   Heart and Stroke Foundation of Canada
Completed - verified May 2015

Get CardioSmart

You're Invited